Found 19 clinical trials
Zoledronate Early to Hip Fracture Patients - Safe and Effective? (ZEBRA)
To prevent hip fracture patients for having another fracture, secondary fracture preventing medication should be given as soon as possible. Zoledronate is the most efficient bisphosphonate and
- 0 views
- 12 Apr, 2023
- 1 location
Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
extension study will offer subjects 12-month administration of open-label alendronate (an oral bisphosphonate) 70 mg once weekly after the initial 12 month administration of romosozumab or placebo. The
- 8 views
- 17 Jun, 2022
- 1 location
Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.
Patients with newly diagnosed or known multiple myeloma with newly diagnosed vertebral lesion(s) will be invited to participate in a cross-sectoral randomized controlled trial. The trial will compare two groups of patients which either receive regular medical treatment of their vertebral lesion(s) or vertebroplasty in addition to regular medical treatment. …
- 0 views
- 29 Sep, 2021
- 1 location
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (BoneZone)
The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in women aged 50 years or older and men aged 70 years or older requiring admission …
- 0 views
- 10 Apr, 2023
- 12 locations
Assessment of Bone Quality After Socket Preservation Using Sodium Alendronate Gel Compared to Sticky Bone
The aim of study to evaluate the quality and quantity of the formed bone after socket preservation using sticky bone versus alendronate gel
- 0 views
- 03 Apr, 2023
- 1 location
Medication-related Osteonecrosis of the Jaw (MRONJ) Registry (MRONJ)
Approximately 500 patients will be included in this patient registry. Data collection includes demographics, clinical data of underlying disease and use of bisphosphonates, denosumab and antiangiogenic drugs , degree and extension of osteonecrosis, osteonecrosis-specific treatment, outcomes and complications within 1 year after treatment.
- 250 views
- 31 Jan, 2022
- 14 locations
Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care
The aim of this study is looking at the Kinetics of bone turnover markers (C-terminal telopeptides of type I collagene (CTX), amino-terminal telopeptide of type 1 collagen (NTX), Dickkopf-1 (DKK-1) and Sclerostin (SOST)) in serum and urine until 12 months in Patients with Multiple Myeloma Treated With intravenous bisphosphonates in …
- 0 views
- 10 Oct, 2021
- 1 location
Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation (BAD)
recommends that patients who discontinue denosumab should continue to receive either intravenous (iv) or oral (peros) bisphosphonate therapy for some time. The study aims to investigate changes in the BMD of
- 28 views
- 17 Mar, 2022
- 1 location
Zoledronate In the Prevention of Paget's Disease: Long Term Extension (ZiPP-LTE)
study is an extension of the ZiPP (Zoledronate in the Prevention of Paget's) study which was is randomised trial currently in progress to determine if the bisphosphonate zoledronic acid (ZA) can prevent
- 172 views
- 03 Feb, 2022
- 2 locations
- 1
- 2